What is Larotrectinib: Uses, Dosage, Side Effects and More

Larotrectinib is a targeted cancer medication that blocks specific proteins helping certain tumors grow. It's designed for cancers with a particular genetic change called TRK fusion, which affects how cells multiply and spread throughout your body.

This medication represents a newer approach to cancer treatment, focusing on the genetic makeup of tumors rather than just their location. When your cancer has the right genetic markers, larotrectinib can be remarkably effective at slowing or stopping tumor growth.

What is Larotrectinib Used For?

Larotrectinib treats solid tumors that have a specific genetic alteration called TRK fusion. This genetic change can occur in many different types of cancer, regardless of where they started in your body.

Your doctor will order special genetic testing on your tumor tissue to determine if larotrectinib is right for you. The medication works for both adults and children whose cancers have spread or can't be removed with surgery.

Common cancer types that may have TRK fusion include certain brain tumors, lung cancers, thyroid cancers, and soft tissue sarcomas. However, this genetic change is relatively rare, occurring in less than 1% of most solid tumors.

How Does Larotrectinib Work?

Larotrectinib blocks proteins called TRK receptors that help cancer cells grow and multiply. When these proteins are overactive due to genetic changes, they send constant "grow" signals to cancer cells.

Think of TRK proteins like a car's gas pedal stuck in the "on" position. Larotrectinib acts like releasing that pedal, stopping the constant growth signals. This targeted approach means it primarily affects cancer cells while leaving healthy cells largely alone.

This medication is considered a strong, precision cancer treatment. It's specifically designed for tumors with TRK fusion, making it highly effective when the genetic match is right.

How Should I Take Larotrectinib?

Take larotrectinib exactly as your doctor prescribes, usually twice daily with or without food. Swallow the capsules whole with water, and don't crush, chew, or open them.

You can take this medication with meals if it helps reduce stomach upset. Try to take your doses at the same times each day to maintain consistent levels in your bloodstream.

If you're taking the liquid form, use the measuring device provided by your pharmacy. Regular household spoons aren't accurate enough for medication dosing.

How Long Should I Take Larotrectinib For?

You'll typically continue taking larotrectinib as long as it's working and you're tolerating it well. Your doctor will monitor your response through regular scans and blood tests.

Most people take this medication for months or years, depending on how their cancer responds. Your treatment team will regularly assess whether the benefits continue to outweigh any side effects you're experiencing.

Never stop taking larotrectinib without discussing it with your doctor first. Stopping suddenly could allow your cancer to start growing again more quickly.

What Are the Side Effects of Larotrectinib?

Most people experience some side effects with larotrectinib, though they're often manageable with proper support. The good news is that serious side effects are less common than with many other cancer treatments.

Here are the most common side effects you might experience:

• Fatigue and feeling more tired than usual
• Dizziness, especially when standing up quickly
• Nausea and occasional vomiting
• Constipation or changes in bowel habits
• Muscle or joint pain
• Changes in taste or decreased appetite
• Mild skin rash or dryness

These common effects usually improve as your body adjusts to the medication. Your healthcare team can provide strategies to help manage these symptoms effectively.

Some people may experience more serious side effects that require immediate medical attention:

• Severe liver problems, causing yellowing of skin or eyes
• Heart rhythm changes or unusual heartbeat
• Severe dizziness or fainting spells
• Significant weight gain or swelling
• Unusual bleeding or bruising
• Severe mood changes or confusion

These serious effects are less common but important to watch for. Contact your doctor immediately if you notice any of these symptoms.

Who Should Not Take Larotrectinib?

Larotrectinib isn't suitable for everyone, even those with TRK fusion-positive cancers. Your doctor will carefully review your medical history before prescribing this medication.

You should not take larotrectinib if you're allergic to the medication or any of its components. People with severe liver disease may need dose adjustments or alternative treatments.

Special consideration is needed if you have heart problems, liver disease, or are taking multiple other medications. Your doctor will weigh the potential benefits against the risks in these situations.

Pregnant or breastfeeding women should discuss alternatives with their healthcare team, as larotrectinib may harm developing babies.

Larotrectinib Brand Names

Larotrectinib is sold under the brand name Vitrakvi in most countries. This is the only approved brand name for this specific medication.

Your pharmacy may have different manufacturers, but the active ingredient remains the same. Always check with your pharmacist if you have questions about the specific version you're receiving.

Larotrectinib Alternatives

For TRK fusion-positive cancers, entrectinib is another targeted therapy option. It works similarly to larotrectinib but may be chosen based on your specific situation or insurance coverage.

If targeted therapy isn't suitable, your doctor might recommend traditional chemotherapy, immunotherapy, or radiation therapy. The best alternative depends on your cancer type, overall health, and previous treatments.

Clinical trials may also offer access to newer experimental treatments. Your oncologist can help you explore all available options for your specific situation.

Is Larotrectinib Better Than Other Cancer Medications?

Larotrectinib can be significantly more effective than traditional treatments for TRK fusion-positive cancers. Studies show response rates of around 75-80% in people with the right genetic markers.

Compared to chemotherapy, larotrectinib often causes fewer severe side effects and may work longer. However, it only works for cancers with TRK fusion, which limits its use to a small percentage of cancer patients.

For people whose tumors have TRK fusion, larotrectinib is often considered the preferred first-line treatment. The key is having the right genetic match between your tumor and the medication.